Analyst sees 30% upside for Lexicon as new trial knowledge boosts sotagliflozin’s prospects By Investing.com
On Wednesday, H.C. Wainwright maintained a optimistic outlook on Lexicon Prescription drugs…
Search
Have an existing account?
Sign In
